CN116949165B - Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof - Google Patents
Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof Download PDFInfo
- Publication number
- CN116949165B CN116949165B CN202310748322.3A CN202310748322A CN116949165B CN 116949165 B CN116949165 B CN 116949165B CN 202310748322 A CN202310748322 A CN 202310748322A CN 116949165 B CN116949165 B CN 116949165B
- Authority
- CN
- China
- Prior art keywords
- anxiety
- depression
- breast cancer
- butyric acid
- morbidity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 60
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 60
- 208000020401 Depressive disease Diseases 0.000 title claims abstract description 55
- 230000002550 fecal effect Effects 0.000 title claims abstract description 16
- 239000003550 marker Substances 0.000 title abstract description 11
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 125
- 210000003608 fece Anatomy 0.000 claims abstract description 34
- 241000894006 Bacteria Species 0.000 claims abstract description 17
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 108020004465 16S ribosomal RNA Proteins 0.000 claims abstract description 12
- 238000012163 sequencing technique Methods 0.000 claims abstract description 11
- 238000011529 RT qPCR Methods 0.000 claims abstract description 9
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims abstract description 8
- 238000004458 analytical method Methods 0.000 claims description 22
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 15
- 238000003745 diagnosis Methods 0.000 claims description 14
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000011002 quantification Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 abstract description 51
- 230000001684 chronic effect Effects 0.000 abstract description 20
- 230000003340 mental effect Effects 0.000 abstract description 18
- 230000000968 intestinal effect Effects 0.000 abstract description 17
- 230000002441 reversible effect Effects 0.000 abstract description 10
- 208000019901 Anxiety disease Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 206010027476 Metastases Diseases 0.000 abstract description 5
- 230000036506 anxiety Effects 0.000 abstract description 5
- 230000009401 metastasis Effects 0.000 abstract description 5
- 230000008451 emotion Effects 0.000 abstract description 4
- 239000000439 tumor marker Substances 0.000 abstract description 4
- 230000006399 behavior Effects 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 2
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 30
- 230000035882 stress Effects 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000037326 chronic stress Effects 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 9
- 206010061309 Neoplasm progression Diseases 0.000 description 7
- 230000007529 anxiety like behavior Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000005751 tumor progression Effects 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 150000004666 short chain fatty acids Chemical class 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012352 Spearman correlation analysis Methods 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 102000017919 ADRB2 Human genes 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102100040133 Free fatty acid receptor 2 Human genes 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 101000959437 Homo sapiens Beta-2 adrenergic receptor Proteins 0.000 description 1
- 101000890668 Homo sapiens Free fatty acid receptor 2 Proteins 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940057344 bufferin Drugs 0.000 description 1
- PASOAYSIZAJOCT-UHFFFAOYSA-N butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O PASOAYSIZAJOCT-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007267 depressive like behavior Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007085 granulocyte colony-stimulating factor production Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/025—Gas chromatography
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention discloses a fecal marker group for evaluating anxiety/depression-breast cancer co-morbidity and application thereof. The inventor finds that the deprivation of intestinal flora can reverse anxiety and depression behaviors and carcinomatous effect caused by chronic mental stress, and the content of Achroman and butyric acid in the faeces of mice in a stress group is obviously reduced. Among 57 breast cancer patients, anxiety and depression states of the patients are evaluated through HADS scoring, 16s rDNA sequencing, qPCR verification and targeted short-chain metabolome detection are carried out on patient faeces, and the fact that the content of Ackermann bacteria and butyric acid in the faeces of the breast cancer patients with anxiety and depression emotion is obviously reduced is found, and the high content of the Ackermann bacteria and the butyric acid is obviously inversely related to the size, grading, distal metastasis, ki67 and tumor marker CA153 expression quantity of the breast cancer. The oral administration of the Ackermans and the sodium butyrate can inhibit the breast cancer progress and anxiety and depression behaviors of the pressure mice, and provide clinical diagnosis and treatment guidance for patients suffering from anxiety/depression-breast cancer.
Description
Technical Field
The invention belongs to the field of medical diagnosis, and particularly relates to a fecal marker group for evaluating anxiety/depression-breast cancer co-morbidity and application thereof.
Background
Clinical studies show that tumor patients often suffer from chronic mental stress, and 54.9% and 49.7% of Chinese cancer patients suffer from chronic mental stress symptoms of depression and anxiety 1 And chronic stress can increase the death risk of tumor patients 2 . Recent studies have shown that chronic mental stress is mainly caused by abnormal release of stress-related hormones through activation of the Sympathetic Nervous System (SNS) and hypothalamic-pituitary-adrenal (HPA) axes, thereby promoting various malignant phenotypes such as tumor metastasis, proliferation, angiogenesis and immune escape 2 . For example, chronic stress may activate the HP A axis to release epinephrine and thereby activate ADRB2 receptor up-regulating MYC transcription activation SLUG, thereby promoting breast cancer dryness 3 . Therefore, the key to improving the tumor treatment effect and improving the life quality of the patient is to pay close attention to the emotion change and psychological state of the tumor patient, provide psychological consultation in time and conduct psychological coaching intervention. The Hospital Anxiety Depression Scale (HADS) is a 'gold standard' for the current clinical self-evaluation of the anxiety depression state of patients, but the scale is highly subjective and is easily interfered by objective factors, and sometimes cannot well reflect the mental and psychological state of the patients, thus delaying the 'gold window' of treatment. Therefore, the search for noninvasive, convenient, objective and accurate anxiety/depression-breast cancer co-morbidity early diagnosis and postoperative detection methods is a constant effort of researchersThe direction of the force.
Detection of changes in the flora in feces is currently a trend in noninvasive diagnosis of tumor patients. Intestinal flora homeostasis plays a key role in maintaining normal physiological functions of the body, and dysbacteriosis can lead to malignant progression of tumors. For example, in comparison to healthy humans, early stage colon cancer patients are enriched in coliform bacteria (expressing clbB) and bacteroides fragilis (expressing bft) secreting oncogenic toxins in the colonic mucosa 4 . Recent studies have found that chronic stress can promote the development of a variety of diseases by interfering with intestinal flora homeostasis. For example, chronic stress causes abnormal release of glucocorticoid to increase intestinal permeability, and further stimulates G-CSF production by activating Th17 cells to release IL-17A by the arthrobacter, promoting sickle cell disease 5 . However, the regulatory mechanisms by which chronic mental stress causes disturbances in the intestinal flora in promoting tumor progression are still unclear.
Recent studies have found that ackermanni is considered a biomarker for healthy intestinal tract 6,7 Its abundance is inversely related to tumor progression 8 . For example, amuc_1100 protein expressed on the outer membrane of Acremonium by promoting CD8 + Expansion and activation of T cells to slow progression of colorectal cancer 9 . In addition, the extramembranous protein Amuc_1100 produced by Ackermana Δ80 Can reduce inflammatory reaction and HPA axis activity by inducing serotonin biosynthesis and activation of 5-HTR1A-CREB-BDNF pathway, thereby relieving depression-like symptoms of mice caused by chronic stress 10 . Although ackermannia can improve the anxiety-depression state induced by chronic mental stress, ackermannia can reverse the tumor progression promoted by chronic mental stress, and is still to be further studied as a new marker for anxiety/depression-breast cancer co-disease diagnosis.
As an important medium for the functions of intestinal flora, the metabolites of the intestinal bacteria play an important role in maintaining the normal physiological homeostasis of the organism, regulating host immunity, metabolism and other aspects of development. Short Chain Fatty Acids (SCFAs) are important intestinal bacteria metabolites, are small molecules synthesized by specific intestinal bacteria through dietary fiber fermentation, and can inhibit tumor progression 11 . For example, butylPromotion of downstream target gene Fas, P21, P27 expression by acid through inhibition of HDAC3 activity causes cell cycle arrest, thereby inducing apoptosis of lymphoma cells 12 . In addition, butyric acid can cause apoptosis in human colon tumor cells by activating the G protein-coupled receptor GPR43 to up-regulate the expression of the pro-apoptotic protein Caspase 3/6/7/8 13 . Recent studies have found that anaplerotic acid in mice can reverse anxiety-depressive behavior due to chronic stress 14 . However, whether in vivo back-patch acid can reverse the carcinomatous effect caused by chronic mental stress and whether butyric acid can be used as a novel marker to evaluate anxiety-depressive states of breast cancer patients remains to be further explored.
Disclosure of Invention
The object of the present invention is to overcome at least one of the disadvantages of the prior art and to provide a fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof.
The technical scheme adopted by the invention is as follows:
in a first aspect of the invention, there is provided:
a fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity consisting of ackerman and butyric acid in feces.
In a second aspect of the invention, there is provided:
the application of the detection reagent in preparing the anxiety/depression-breast cancer co-morbidity diagnosis reagent is characterized in that a sample detected by the detection reagent is feces, and quantitative markers are Ackermans bacteria and butyric acid in the feces.
In some examples of application, the ackermannia is quantified by methods of metagenomics, 16s rDNA sequencing (16 s rDNA seq) or qPCR.
In some examples of applications, butyric acid is quantified by gas chromatography-mass spectrometry (GC-MS).
In a third aspect of the invention, there is provided:
a system for assessing anxiety/depression-breast cancer co-morbidity comprising:
the quantifying device is used for quantifying the content of the Acremonium and the butyric acid in the fecal sample;
an analysis device for evaluating the risk of anxiety/depression-breast cancer co-morbidity based on the quantitative result of the quantitative device;
and a result output device for outputting the analysis result of the analysis device.
In some examples of the system, the quantification device comprises a macrogenomic device to quantify ackermannia, a 16s rDNA seq quantification or a qPCR analysis device.
In some examples of the system, the quantification device comprises a GC-MS device that quantifies butyric acid.
In some examples of the system, the amounts of ackermanni and butyric acid were significantly reduced, indicating a high risk of anxiety/depression-breast cancer co-morbidity.
In some system examples, acremonium DNA content greater than or equal to 1.382 μg/g patient stool DNA and butyric acid content greater than or equal to 1080 μg/g patient stool, indicating low anxiety depression.
In a fourth aspect of the invention, there is provided:
a composition for improving anxiety/depression-breast cancer co-morbidity symptoms comprises an active ingredient and acceptable auxiliary materials, wherein the active ingredient is Acremonium and pharmaceutically acceptable butyrate.
In some examples of compositions, the ratio of ackermanni to butyric acid is: the gastric lavage dosage of the Ackermana is (1-9) multiplied by 10 8 CFU, pharmaceutically acceptable butyrate, is used in the form of (100-400) mg/kg.
In some examples of compositions, the pharmaceutically acceptable butyrate is sodium butyrate.
The beneficial effects of the invention are as follows:
the invention breaks through the limitation that anxiety/depression can be determined only through subjective evaluation in the prior art, and discovers that a specific fecal marker can be used as an objective index for evaluating the risk of anxiety/depression-breast cancer co-morbidity, and is hopeful to obtain a more accurate result.
Based on the earlier study foundation, the inventors first constructed a mouse model of anxiety/depression-breast cancer co-morbidity. Meanwhile, in order to study the role of intestinal flora in promoting tumor progression by chronic mental stress,a sterile mouse model of intestinal flora colonization was used and subcutaneously tumorigenic female mice were randomly divided into a specific pathogen free (Specific pathogen Free, SPF) mouse control group, an SPF mouse-imposed chronic stress group, a sterile (Germ-free, GF) mouse control group and a GF mouse-imposed chronic stress group. The detection result of the behavioural experiment shows that the mice in the stress group show obvious anxiety-like behavior compared with the mice in the control group in the SPF mice, and the tumor volume of the mice treated by the confinement is obviously larger than that of the mice in the control group. Whereas deprivation of intestinal flora in GF mice reversed anxiety-like behavior due to chronic mental stress and reversed the promotion of tumor by stress (fig. 1). Then, metagenome sequencing is carried out by collecting the faeces of the SPF mice in the pressure group and the control group mice, and the Ackermania in the faeces of the mice in the pressure group is found outAkkermansia mucinphila) The abundance decreases significantly. Based on the results of KEGG pathway enrichment analysis of the sequencing results, the inventors performed Short Chain Fatty Acid (SCFAs) targeted metabonomics detection of mouse faeces and breast cancer tumor tissue, and found that the butyric acid (butyl acid) content in faeces and tumor tissue from pressure group mice was significantly reduced. Spearman correlation analysis showed that the abundance of ackerman was positively correlated with the amount of butyric acid in mouse faeces and tumors (figure 2).
To demonstrate that ackerman and butyric acid found in the mouse experiments can be used as non-invasive molecular markers for diagnosis of anxiety/depression-breast cancer co-morbidity, the inventors recruited 57 breast cancer patients, and evaluated their anxiety-depression status by HADS scoring the patients. By 16s rDNA sequencing of the faeces of clinical patients, the abundance of Ackermana in the faeces of breast cancer patients with anxiety-depression emotion was found to be significantly reduced, while the results of the targeted metabonomics also indicate that the butyric acid content in the faeces of breast cancer patients with anxiety-depression was significantly reduced (figure 3). Spearman correlation analysis showed that the abundance of ackerman bacteria in the feces was significantly positively correlated with the butyrate content, while HADS scores were significantly negatively correlated with the ackerman bacteria abundance and butyrate content in the patient's feces (fig. 4). Next, the inventors rank the patients according to the abundance of ackermannia and the content of butyric acid, and classify the patients into ackermannia high (high) and ackermannia low (low), butyric acid high (high) and butyric acid low (low). Patients with ackerman high and butyric acid high were found to be significantly inversely related to tumor size, grade, distant metastasis, ki67, tumor marker CA153 (tables 1 and 2).
The inventor in the mouse experiment finds that the in vivo anaplerosis and butyric acid can significantly reverse the tumor progress promoted by chronic mental stress through the gastric lavage mode, and can reverse the anxiety-like behavior (figure 5) of the mouse caused by chronic stress, and the studies show that the anaplerosis and the butyric acid can be used for noninvasive molecular markers for diagnosis of anxiety/depression-breast cancer co-morbidity, and can better guide clinical medication.
Drawings
FIG. 1 is the results of a gut flora-mediated chronic mental stress to promote tumor growth and a mouse behavioral assay.
Figure 2 is the result of mouse fecal metagenomics and targeted metabolomics.
FIG. 3 shows the results of stool 16s rDNA sequencing and targeted metabonomics from breast cancer patients.
FIG. 4 shows the results of analysis of correlation between HADS and Acremonium abundance and butyric acid content.
FIG. 5 is the result of anaplerotic Achroman and butyric acid reversal of chronic mental stress cancer promotion.
Detailed Description
In a first aspect of the invention, there is provided:
a fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity consisting of ackerman and butyric acid in feces.
In a second aspect of the invention, there is provided:
the application of the detection reagent in preparing the anxiety/depression-breast cancer co-morbidity diagnosis reagent is characterized in that a sample detected by the detection reagent is feces, and quantitative markers are Ackermans bacteria and butyric acid in the feces.
The method of quantifying ackermanni may be an existing method. In some examples of application, ackermannia is quantified by methods of metagenomics, 16s rDNA seq, or qPCR. These methods are relatively mature, reliable in detection results and low in cost.
The method for quantifying butyric acid may be an existing method. In some examples of applications, butyric acid is quantified by GC-MS method. These methods are relatively mature, reliable in detection results and low in cost.
In a third aspect of the invention, there is provided:
a system for assessing anxiety/depression-breast cancer co-morbidity comprising:
the quantitative device is used for quantifying the amounts of the Acremonium and the butyric acid in the fecal sample;
an analysis device for evaluating the risk of anxiety/depression-breast cancer co-morbidity based on the quantitative result of the quantitative device;
and a result output device for outputting the analysis result of the analysis device.
In some examples of the system, the quantification device comprises a macrogenomic device to quantify ackermannia, a 16s rDNA seq quantification or a qPCR analysis device.
In some examples of the system, the quantification device comprises a GC-MS device that quantifies butyric acid.
The quantitative device is mature, and the reliability of the detection result is high. Of course, other known dosing devices may be used.
In some examples of the system, the amounts of ackermanni and butyric acid were significantly reduced, indicating a high risk of anxiety/depression-breast cancer co-morbidity. Significantly reduced to what is known in the art means that the amount of ackermanni or butyric acid is below the median, or below the average level.
In some system examples, acremonium DNA content greater than or equal to 1.382 μg/g patient stool DNA and butyric acid content greater than or equal to 1080 μg/g patient stool, indicating low anxiety depression.
In a fourth aspect of the invention, there is provided:
a composition for improving anxiety/depression-breast cancer co-morbidity symptoms comprises an active ingredient and acceptable auxiliary materials, wherein the active ingredient is Acremonium and pharmaceutically acceptable butyrate.
In some examples of compositions, the composition is a gastric lavage or an oral dosage.
In some examples of compositions, the ratio of ackermanni to pharmaceutically acceptable butyrate is: the gastric lavage dosage of the Ackermana is (1-9) multiplied by 10 8 CFU and butyric acid are used for lavage (100-400) mg/kg.
The pharmaceutically acceptable butyrate may be various pharmaceutically acceptable salts, such as sodium, potassium, calcium, zinc salts, and in some examples of compositions, the pharmaceutically acceptable butyrate is sodium butyrate. Sodium butyrate is low in price, has better water solubility and is a better choice.
The technical scheme of the invention is further described below in conjunction with experiments.
1. Construction and verification of chronic mental stress mouse model
Animal experiments are strictly referred to the management requirements of the tumor animal experiment center of Dalian medical university and are implemented after ethical examination. To construct a mouse model of anxiety/depression-breast cancer co-morbidity, the inventors randomly divided SPF mice and GF mice into 4 groups, SPF mouse control group, SPF mouse-applied chronic stress group, GF mouse control group, GF mice-applied chronic stress group (10 per group). Py8119-pLVX-MCS-Luc2 cells from mice were pre-treated with chronic confinement for 1 week and 1X 10 per 100. Mu.l 5 The concentration of individual cells was resuspended in PBS buffer and the cells were inoculated subcutaneously into the backs of 7 week old female mice. The tumor growth of the mice was recorded after the transplanted tumors had grown to an average diameter of about 3 mm. The mice in the stress group were subjected to the confinement experiment for 6 hours each day for 4 weeks without undue stress and injury to the mice during the confinement experiment (fig. 1, A).
Anxiety-like behavior of the chronic stress mice is detected through an open field and elevated plus maze behavioural experiment, and whether the chronic stress modeling is successful is evaluated. a. Open field experiments: the open field experimental device is divided into a central area and a peripheral area. At the beginning of the experiment, the mice were placed at the corners of the peripheral area and after free movement for 5 minutes, anxiety states of the mice were reflected by analyzing data such as the moving distance, standing times, and center residence time of the mice. b: overhead plus maze experiment: overhead cross maze experimental deviceThe device consists of an open arm and a closed arm. At the beginning of the experiment, mice were left on the central platform to explore freely for 5 minutes, and the time and distance of movement into the open and closed arms were recorded to reflect the anxiety state of the mice. The behavioral test results indicate that stress group mice exhibited anxiety-like behavior in SPF mice, while elimination of intestinal flora in GF mice significantly reversed stress-induced anxiety-like behavior in mice (fig. 1B and C). The tumor volume of the mice was measured once every two days according to the formula v= (long diameter x short diameter 2 ) And (2) calculating. Both the in vivo imaging results of mice and the tumorigenic profile of tumors showed that the tumor volume of the pressure group mice was significantly greater than the control group in SPF mice, while deprivation of intestinal flora was able to significantly reverse the tumor promotion by pressure (fig. 1D and E). The experimental results show that the chronic mental stress can further cause anxiety depression-like behaviors of the mice by influencing the homeostasis of intestinal flora of the mice and finally promote the tumor progression of the mice with breast cancer, and the elimination of the intestinal flora in the mice can reverse the promotion effect of the chronic mental stress on the tumor of the mice with breast cancer.
2. Mouse fecal metagenomic and targeted metabonomic analysis
To further investigate the effect of chronic mental stress on the intestinal flora of mice, the inventors collected fresh faeces of mice and frozen faecal samples in liquid nitrogen. The total DNA of microorganisms in the feces was extracted using an e.z.n.a. oven DNA Kit (D4015-02, omega, inc., USA) Kit, and the quality of DNA extraction was detected by agarose gel electrophoresis, while the DNA was quantified using an ultraviolet spectrophotometer. Macrogenomic sequencing is carried out on the extracted fecal DNA, and the analysis result of LEfSe (lineardiscriminant analysis (LDA) effect size) shows that the Ackermania in the feces of the mice in the pressure group at the seed levelAkkermansia mucinphila) The significantly reduced abundance (fig. 2A and B), the results of qPCR of mouse fecal DNA also demonstrated a significant decrease in ackermannia abundance under stress (fig. 2C), indicating that ackermannia abundance was most significantly altered by stress in the breast cancer mouse model. Further the inventors performed KEGG pathway enrichment analysis on the sequencing results, found that fatty acid synthesis in the 10 th position before the changeThe pathways and fatty acid metabolic pathways were significantly enriched (fig. 2D). Based on the analysis results of KEGG, the inventors performed SCFAs-targeted metabonomics detection on the faeces and breast cancer tumor tissue of mice, and found that the butyric acid (butyric acid) content in the faeces and tumor tissue of pressure group mice was significantly reduced (fig. 2E and F). Meanwhile, the Spearman correlation analysis result shows that the abundance of the ackerman bacteria in the mouse feces is obviously and positively correlated with the content of the butyric acid in the feces and the content of the butyric acid in the tumor tissues (figures 2G and H).
3. Fecal 16s rDNA sequencing and targeted metabonomics analysis of breast cancer patients
After obtaining approval by the ethical review Committee of the affiliated second hospital of Dalian medical university, the inventors collected stool samples from 57 breast cancer patients in total for evaluation of the abundance of Ackermans and the butyric acid content in the stool. Furthermore, to further demonstrate that ackerman and butyric acid in the stool of patients can be used as non-invasive molecular markers for diagnosis of anxiety/depression-breast cancer co-diseased patients, the inventors performed HADS scoring on 57 breast cancer patients to assess anxiety-depression status of the patients. According to the criteria, a score of 10 was defined as no/low anxiety depression patients (HADS low) and a score of > 10 was defined as medium/severe anxiety depression patients (HADS high).
Next, the collected feces of 57 patients were subjected to DNA extraction and 16s rDNA sequencing, and the analysis result of volcanic chart showed that the abundance of ackermannin bacteria in feces was significantly reduced in breast cancer patients suffering from moderate/severe anxiety depression emotion (fig. 3A), the same conclusion was drawn from the heat chart analysis result (fig. 3B), and the result of qPCR also showed that the content of ackermannin bacteria was significantly reduced in feces from breast cancer patients suffering from anxiety depression (fig. 3C). Further examination of stool SCFAs using targeted metabonomics, the analysis also showed a significant decrease in butyrate content in the stool of patients with anxiety-depression breast cancer (figure 3D), consistent with the results obtained in the mouse experiments. Spearman correlation analysis showed that the abundance of ackerman bacteria in the stool was significantly positively correlated with the butyrate content (fig. 4A), while HADS scores were significantly negatively correlated with ackerman bacteria abundance and butyrate content in the stool (fig. 4B and C). To further confirm that ackerman and butyric acid can be novel markers of anxiety/depression-breast cancer co-morbidity, the inventors rank the patients according to abundance of ackerman and content of butyric acid, and take median as a boundary value, and divide the patients into ackerman high and ackerman low, butyric acid high and butyric acid low. The high ackermann abundance and butyrate content were found to be significantly inversely correlated with tumor size, grade, distant metastasis, ki67, tumor marker CA153 (tables 1 and 2).
TABLE 1 correlation of Ackermansia with clinical indicators
Statistical significance was determined by a two-tailed unpaired Student's t test.
TABLE 2 correlation of butyric acid with clinical indicators
Statistical significance was determined by a two-tailed unpaired Student's t test.
The research results show that the marker composed of the intestinal flora Acremonium and the metabolite butyric acid thereof in the feces can well reflect the anxiety depression degree of a breast cancer patient, can accurately predict the tumor grading and metastasis risks of the breast cancer patient, and can serve as a new tumor marker for noninvasive diagnosis of the breast cancer.
4. Analysis of effects of anaplerotic ackerman and butyric acid in mouse transplantation tumor model
Finally, the inventor verifies in a mouse model through in vivo anaplerotic ackermanni and sodium butyrate. The inventors randomly divided mice into 4 groups, control group, chronic stress group, and Hui's Ackermans group (3×10) 8 CFU/day), pressure and pressure supplemented Ackermans group (3×10) 8 CFU/day, 8 per group). After 1 week of chronic confinement pretreatment, mice-derived Py8119-pLVX-MCS-Luc2 cells were enriched with 1X 10 per 50. Mu.l 5 Concentration of individual cells resuspended in PBS bufferIn solution, and cells were inoculated in situ into the fourth pair of mammary fat pads of 7 week old female mice (fig. 5A). The tumor growth of the mice was recorded after the transplanted tumors had grown to an average diameter of about 3 mm. The inventors found that anaplerotic ackermannia was able to reverse chronic stress induced anxiety-like behavior in mice by intragastric administration (fig. 5B and C), and that in vivo imaging results and mouse tumorigenesis curves indicate that anaplerotic ackermannia was able to significantly reverse chronic stress-promoted tumor progression (fig. 5D and E). At the same time, similar results were found in the control, chronic stress, anaplerotic sodium butyrate (200 mg/kg/day), and pressure plus anaplerotic sodium butyrate (8 per group) 4 experiments (FIG. 5F-J). These results indicate that ackerman and butyric acid can be used as non-invasive molecular markers for diagnosis of anxiety/depression-breast cancer co-morbidity and better guide clinical medication.
In conclusion, experimental data show that quantitative analysis of the abundance and the butyric acid content of the Ackermans in the feces provides a novel high-sensitivity and specific detection index for diagnosis of patients suffering from anxiety/depression-breast cancer, has a good diagnosis value for the patients suffering from anxiety/depression, reduces missed diagnosis, and simultaneously, the Ackermans and the butyric acid can be used as good independent prognosis prediction indexes, thereby providing a novel approach for diagnosing anxiety depression states and predicting of the patients suffering from breast cancer.
The above description of the present invention is further illustrated in detail and should not be taken as limiting the practice of the present invention. It is within the scope of the present invention for those skilled in the art to make simple deductions or substitutions without departing from the concept of the present invention.
Reference is made to:
1. Du, L., et al.Incidence of suicide death in patients with cancer: A systematic review and meta-analysis.J Affect Disord276, 711-719 (2020).
2. Cui, B., et al.Cancer and stress: NextGen strategies.Brain Behav Immun93, 368-383 (2021).
3. Cui, B., et al.Stress-induced epinephrine enhances lactate dehydrogenase A and promotes breast cancer stem-like cells.J Clin Invest129, 1030-1046 (2019).
4. Dejea, C.M., et al.Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria.Science359, 592-597 (2018).
5. Xu, C., Lee, S.K., Zhang, D.&Frenette, P.S. The Gut Microbiome Regulates Psychological-Stress-Induced Inflammation.Immunity53, 417-428 e414 (2020).
6. Belzer, C.&de Vos, W.M. Microbes inside--from diversity to function: the case of Akkermansia.ISME J6, 1449-1458 (2012).
7. Ottman, N., et al.Genome-Scale Model and Omics Analysis of Metabolic Capacities of Akkermansia muciniphila Reveal a Preferential Mucin-Degrading Lifestyle.Appl Environ Microbiol83(2017).
8. Ding, Y., et al.A next-generation probiotic: Akkermansia muciniphila ameliorates chronic stress-induced depressive-like behavior in mice by regulating gutmicrobiota and metabolites.Appl Microbiol Biotechnol105, 8411-8426 (2021).
9. Wang, L., et al.A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation ofCD8(+) T cells in mice.Gut69, 1988-1997 (2020).
10. Cheng, R., Zhu, H., Sun, Y., Hang, T.&Zhang, M. The modified outer membrane protein Amuc_1100 of Akkermansiamuciniphila improves chronic stress-induced anxiety and depression-like behavior in mice.Food Funct13, 10748-10758 (2022).
11. Koh, A., De Vadder, F., Kovatcheva-Datchary, P.&Backhed, F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites.Cell165, 1332-1345 (2016).
12. Wei, W., Sun, W., Yu, S., Yang, Y.&Ai, L. Butyrate production from high-fiber diet protects against lymphoma tumor.Leuk Lymphoma57, 2401-2408 (2016).
13. Tang, Y., Chen, Y., Jiang, H., Robbins, G.T.&Nie, D. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer.Int J Cancer128, 847-856 (2011).
14. Li, H., et al.Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors inadolescent rat.J Neuroinflammation18, 254 (2021).。
Claims (9)
1. the application of the detection reagent in preparing the diagnosis reagent for the anxiety/depression-breast cancer co-morbidity of the breast cancer patients is characterized in that a sample detected by the detection reagent is feces, and quantitative markers are Ackermans bacteria and butyric acid in the feces.
2. The use according to claim 1, characterized in that the quantification of ackermannia is performed by means of metagenomics, 16s rDNA sequencing or qPCR.
3. The use according to claim 1, characterized in that the butyric acid is quantified by means of a gas chromatography-mass spectrometry combination.
4. A system for predicting anxiety/depression in a breast cancer patient, comprising:
the quantitative device is used for quantifying the amounts of the Acremonium and the butyric acid in the fecal sample;
an analysis device for evaluating the risk of anxiety/depression-breast cancer co-morbidity based on the quantitative result of the quantitative device;
and a result output device for outputting the analysis result of the analysis device.
5. The system of claim 4, wherein the quantifying means comprises:
a macrogenomic apparatus for quantifying ackermann bacteria, a 16s rDNA seq quantification or qPCR analysis apparatus; and/or GC-MS device for quantifying butyric acid.
6. The system of claim 4, wherein a significant decrease in the amount of ackerman and butyric acid is indicative of a high risk of anxiety/depression-breast cancer co-morbidity.
7. The system of claim 4, wherein an ackermannia DNA content of greater than or equal to 1.382 μg per 1g patient stool DNA and a butyric acid content of greater than or equal to 1080 μg per 1g patient stool is indicative of low anxiety depression.
8. A composition for improving anxiety/depression-breast cancer co-morbidity symptoms comprises an active ingredient and acceptable auxiliary materials, and is characterized in that the active ingredient is Acremonium and pharmaceutically acceptable butyrate.
9. The composition of claim 8, wherein the ratio of ackermanni to sodium butyrate is: the gastric lavage dose of Ackermana is 1×10 8 CFU to 9×10 8 CFU, a pharmaceutically acceptable butyrate, was used at a lavage dose of 100 mg/kg to 400 mg/kg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310748322.3A CN116949165B (en) | 2023-06-25 | 2023-06-25 | Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310748322.3A CN116949165B (en) | 2023-06-25 | 2023-06-25 | Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116949165A CN116949165A (en) | 2023-10-27 |
| CN116949165B true CN116949165B (en) | 2024-04-02 |
Family
ID=88457384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310748322.3A Active CN116949165B (en) | 2023-06-25 | 2023-06-25 | Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116949165B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111920793A (en) * | 2019-04-25 | 2020-11-13 | 瑞微（深圳）生物科技有限公司 | Use of pantothenic acid for preparing composition for treating and/or preventing tumor |
| WO2021176036A1 (en) * | 2020-03-06 | 2021-09-10 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie E. V. Hans-Knöll-Institut (Hki) | Method for the modulation of cancer treatment based on analyzing the gut microbiome |
| CN113645981A (en) * | 2018-11-21 | 2021-11-12 | 德克萨斯大学系统董事会 | Methods and compositions for treating cancer |
| WO2022178193A2 (en) * | 2021-02-17 | 2022-08-25 | Seres Therapeutics, Inc. | Use of immunotherapy and microbiome modulation to treat cancer |
| CN115487214A (en) * | 2022-10-11 | 2022-12-20 | 武汉微康益生菌研究院有限公司 | Application of bacillus coagulans BC99 in relieving diarrhea-predominant irritable bowel syndrome |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3047029A1 (en) * | 2016-12-22 | 2018-06-28 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment |
-
2023
- 2023-06-25 CN CN202310748322.3A patent/CN116949165B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113645981A (en) * | 2018-11-21 | 2021-11-12 | 德克萨斯大学系统董事会 | Methods and compositions for treating cancer |
| CN111920793A (en) * | 2019-04-25 | 2020-11-13 | 瑞微（深圳）生物科技有限公司 | Use of pantothenic acid for preparing composition for treating and/or preventing tumor |
| WO2021176036A1 (en) * | 2020-03-06 | 2021-09-10 | Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie E. V. Hans-Knöll-Institut (Hki) | Method for the modulation of cancer treatment based on analyzing the gut microbiome |
| WO2022178193A2 (en) * | 2021-02-17 | 2022-08-25 | Seres Therapeutics, Inc. | Use of immunotherapy and microbiome modulation to treat cancer |
| CN115487214A (en) * | 2022-10-11 | 2022-12-20 | 武汉微康益生菌研究院有限公司 | Application of bacillus coagulans BC99 in relieving diarrhea-predominant irritable bowel syndrome |
Non-Patent Citations (3)
| Title |
|---|
| Akkermansia Muciniphilia减轻放射性肠道损伤的作用及其机制研究;菅永平;《中国博士学位论文全文数据库（电子期刊）医药卫生科技辑》;20230115;第2023年卷(第1期);文章号E076-5 * |
| Maternal n-3 polyunsaturated fatty acids restructure gut microbiota of offspring mice and decrease their susceptibility to mammary gland cancer;Jiaomei Li et al.;《Food & function》;20210907;第12卷(第17期);第8154-8168页 * |
| Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction;C Cristiano et al.;《Biomedicine & pharmacotherapy》;20220930;第153卷;文章号113528 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116949165A (en) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qi et al. | Intestinal permeability biomarker zonulin is elevated in healthy aging | |
| Pluznick | Gut microbiota in renal physiology: focus on short-chain fatty acids and their receptors | |
| O’Gorman et al. | Improvement in histological endpoints of MAFLD following a 12‐week aerobic exercise intervention | |
| Villanueva-Millán et al. | Gut microbiota: a key player in health and disease. A review focused on obesity | |
| Fuller et al. | The CROES percutaneous nephrolithotomy global study: the influence of body mass index on outcome | |
| Hsu et al. | Role of skin and gut microbiota in the pathogenesis of psoriasis, an inflammatory skin disease | |
| Shen et al. | Different host-specific responses in thyroid function and gut microbiota modulation between diet-induced obese and normal mice given the same dose of iodine | |
| O'Shea et al. | The effect of algal polysaccharides laminarin and fucoidan on colonic pathology, cytokine gene expression and Enterobacteriaceae in a dextran sodium sulfate-challenged porcine model | |
| Thomas et al. | Why exercise has a crucial role in cancer prevention, risk reduction and improved outcomes | |
| Li et al. | Targeting PDE4 as a promising therapeutic strategy in chronic ulcerative colitis through modulating mucosal homeostasis | |
| Cordes et al. | MicroRNA-320a strengthens intestinal barrier function and follows the course of experimental colitis | |
| Summers et al. | Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p‐cresol sulfate | |
| Tacchino et al. | Body composition and energy expenditure: relationship and changes in obese subjects before and after biliopancreatic diversion | |
| Reljic et al. | Feasibility, safety, and preliminary efficacy of very low-volume interval training in advanced cancer patients | |
| CN116949165B (en) | Fecal marker panel for assessing anxiety/depression-breast cancer co-morbidity and uses thereof | |
| Goodenough et al. | Associations between exercise capacity, p16INK4a expression and inflammation among adult survivors of childhood cancer | |
| Chapman | The role of the colonic flora in maintaining a healthy large bowel mucosa. | |
| CN108926579A (en) | Liquid oral probiotics preparation and its preparation method and application | |
| Suginohara et al. | Ninjin’yoeito suppressed the onset of arthritis, pain, and muscle atrophy in rheumatoid arthritis model mice | |
| Liu et al. | Revisiting the role of valeric acid in manipulating ulcerative colitis | |
| Gu et al. | Effects of vitamin D3 on intestinal Flora in a mouse model of inflammatory bowel Disease treated with Rifaximin | |
| RU2526796C2 (en) | Method for prediction of clinical effectiveness of patients with non-hodgkin lymphomas with bone marrow involvement | |
| Dodiyi-Manuel et al. | Predispositions of carcinoma of the breast: A review | |
| Chen et al. | Sarcopenia increases the risk of early biliary infection after percutaneous transhepatic biliary stent placement | |
| Rizany et al. | Serum Vitamin D Levels, Visual Analog Scale Dysmenorrhea Score, and Endometriosis ASRM Classification: a Relationship Study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |